Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 10/20 | 0.45 |
| ▸ | CALCR | P30988 | 10/20 | 0.45 |
| ▸ | NPY2R | P49146 | 7/20 | 0.44 |
| ▸ | NPY4R | P50391 | 7/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.44 |
| ▸ | NPY1R | P25929 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433217 | 0.97 | RAMP3 (0.45) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433374 | 0.95 | RAMP3 (0.47) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433309 | 0.95 | RAMP3 (0.48) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433214 | 0.92 | RAMP3 (0.48) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433362 | 0.91 | RAMP3 (0.47) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433211 | 0.91 | RAMP3 (0.44) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433197 | 0.90 | MAPK8 (0.50) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433278 | 0.90 | MAPK8 (0.50) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433294 | 0.89 | MAPK8 (0.49) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31433297 | 0.89 | MAPK8 (0.50) | RAMP3CALCRNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | RAMP3 2637/4885CALCR 2817/4885NPY2R 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.